Edition:
United Kingdom

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

174.88USD
17 Nov 2017
Change (% chg)

$0.07 (+0.04%)
Prev Close
$174.81
Open
$174.00
Day's High
$176.21
Day's Low
$172.87
Volume
699,723
Avg. Vol
584,654
52-wk High
$256.78
52-wk Low
$169.61

Latest Key Developments (Source: Significant Developments)

‍GIC Private reports a 5.11 pct passive stake in Allergan ​
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Allergan Plc :As of Nov 8, ‍GIC Private reports a 5.11 pct passive stake in - SEC filing ​.  Full Article

Allergan receives FDA approval for use of Vraylar in maintenance treatment of schizophrenia
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Allergan Plc :Allergan receives FDA approval for use of Vraylar (cariprazine) in the maintenance treatment of schizophrenia.Allergan - ‍Vraylar is approved in U.S. in adults for acute treatment of schizophrenia & acute treatment of manic/ mixed episodes of bipolar I disorder​.  Full Article

Amgen and Allergan receive positive chmp opinion for ABP 215
Friday, 10 Nov 2017 

Nov 10 (Reuters) - Allergan Plc :Amgen and Allergan receive positive CHMP opinion for ABP 215 (biosimilar bevacizumab) for the treatment of certain types of cancer.Amgen Inc - ‍CHMP positive opinion will now be reviewed by European Commission, which has authority to approve medicines for European Union​.  Full Article

Teva Pharmaceutical Q3 GAAP earnings per share $0.52
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Teva Pharmaceutical Industries Ltd :Teva reports third quarter 2017 financial results.Q3 non-GAAP earnings per share $1.00.Q3 GAAP earnings per share $0.52.Q3 revenue rose 1 percent to $5.6 billion.Generic medicines revenues in Q3 of 2017 were $3.0 billion, a decrease of 8% compared to Q3 of 2016​.Specialty medicines revenues in Q3 of 2017 were $2.0 billion, down 1% compared to Q3 of 2016​.Qtrly ‍global revenues of copaxone were $1.0 billion, a decrease of 7% compared to q3 of 2016​.2017 outlook revised to non-GAAP EPS of $3.77 - $3.87​.Adjustments of exchange rates used for Venezuelan Bolivar resulted in a decrease of $243 million in revenues for quarter​.Net non-GAAP adjustments in Q3 of 2017 were $482 million​.Sees FY‍ revenues $22.2 billion​-22.3 billion​.Sees lower FY cash flow from operations due to reduction in net income, delay in resolution of working capital dispute with Allergan​.Resolution of working capital dispute with Allergan, now scheduled to conclude in 2018​.Q3 earnings per share view $1.06, revenue view $5.67 billion -- Thomson Reuters I/B/E/S.FY2017 earnings per share view $4.12, revenue view $22.63 billion -- Thomson Reuters I/B/E/S.Sees FY cash flow from operations $3.15 billion -$3.3 billion‍​.  Full Article

Allergan gives 2018 guidance based on Restasis competition
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Allergan Plc :Says expects 2018 non-GAAP EPS of no less than $15 if a Restasis generic competitor launches in january 2018.Says expects 2018 non-GAAP EPS of no less than $16 if a Restasis generic competitor launches in july 2018.Says expects 2018 non-GAAP EPS to be higher than 2017 if no Restasis generic competitor launches in 2018.Says expects 2019 non-GAAP EPS to be higher than 2017 regardless of when a Restasis generic competitor launches.  Full Article

Allergan reports Q3 revenue $4.03 bln, up 11 pct
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Allergan Plc :Allergan reports solid top-line execution in third quarter 2017 with 11% increase in GAAP net revenues to $4.03 billion.Q3 revenue $4.03 billion versus I/B/E/S view $4.03 billion.Allergan plc - ‍Q3 2017 GAAP continuing operations loss per share of $12.05​.Allergan Plc - ‍Q3 non-GAAP performance net income per share of $4.15​.Allergan Plc - ‍company narrows full-year 2017 non-GAAP net revenue and full-year 2017 non-GAAP performance net income per share guidance​.Q3 earnings per share view $4.05 -- Thomson Reuters I/B/E/S.Allergan-Included within other income (expense), net in three months ended sept 30 is other-than-temporary impairment of teva securities of $1.3 billion.Allergan Plc - sees FY GAAP total net revenues $15,875 million – $16,025 million‍​.Fy2017 revenue view $15.89 billion -- Thomson Reuters I/B/E/S.Allergan Plc - sees FY non-GAAP earnings per share $16.15 - $16.45‍​.Allergan Plc - sees FY GAAP net loss per share $20.05 - $20.35.FY2017 earnings per share view $16.21 -- Thomson Reuters I/B/E/S.Allergan Plc - recognized an impairment of $3.2 billion related to restasis in the three months ended september 30, 2017‍​.Allergan-Also recognized impairment of $164.0 million related to other dry eye ipr&d assets in three months ended september 30, 2017.  Full Article

Allergan receives approval for Ozurdex in China for treatment of retinal vein occlusion
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Allergan Plc -:Allergan receives approval for Ozurdex® (dexamethasone intravitreal implant 0.7 mg) in China for the treatment of retinal vein occlusion (RVO).Allergan Plc - ‍received imported drugs license from Chinese Food And Drug Administration to market Ozurdex​.  Full Article

Allergan announces Q4 2017 cash dividend; increases qtrly cash dividend for 2018
Friday, 27 Oct 2017 

Oct 27 (Reuters) - Allergan Plc :Allergan board of directors announces fourth quarter 2017 cash dividend and increases quarterly cash dividend for 2018.Allergan plc - ‍has approved an increase to its quarterly cash dividend for 2018 to $0.72 per ordinary share​.  Full Article

Syndax Pharma enters into license agreement with unit of Allergan
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - Syndax Pharmaceuticals :On Oct 13, co entered into license agreement with Vitae Pharmaceuticals, a subsidiary of Allergan Plc​ - SEC filing.Pursuant to agreement, co will make an upfront payment of $5.0 million to Allergan​.If parties commercialize Menin assets, co obligated to pay Allergan low single to low double-digit royalties on sales​.Under agreement, Allergan grants co worldwide license to portfolio of orally-available small molecule inhibitors of interaction of MLL protein​.Under agreement, may have to pay allergan up to $99 million in one-time development, regulatory milestone payments subject to achievement of milestones.In event of commercializing Menin assets, co to also pay up to $70 million in potential one-time sales-based milestone payments​.Company will be solely responsible for development and commercialization of Menin assets​.Under certain circumstances, co may be required to share a percentage of non-royalty income from sublicensees, with Allergan​.  Full Article

Syndax Pharmaceuticals says ‍expands pipeline with exclusive worldwide license to Allergan's portfolio of Menin-MLL inhibitors​
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - Syndax Pharmaceuticals Inc ::Syndax Pharmaceuticals Inc - ‍expands pipeline with exclusive worldwide license to Allergan's portfolio of Menin-MLL inhibitors​.Syndax Pharmaceuticals Inc - ‍ entered into an exclusive worldwide license agreement with Vitae Pharmaceuticals, inc., a subsidiary of Allergan PLC​.  Full Article

BRIEF-‍GIC Private reports a 5.11 pct passive stake in Allergan ​

* As of Nov 8, ‍GIC Private reports a 5.11 pct passive stake in - SEC filing ​ Source text: (http://bit.ly/2zMOtvp) Further company coverage: